Stocksigma LogoStocksigma Logo

JHS Svendgaard Laboratories Reports Fund Allocation Variations for Preferential Issue Proceeds

JHS Svendgaard Laboratories Limited disclosed shareholder-approved modifications, dated 29th Jul'26, regarding the utilization of ₹29.99 crore raised via a

JHS Svendgaard Laboratories Reports Fund Allocation Variations for Preferential Issue Proceeds

JHS Svendgaard Laboratories Ltd · Others (Uncategorized) · 03 Nov 2026, 12:27 am

JHS Svendgaard Laboratories Reports Fund Allocation Variations for Preferential Issue Proceeds JHS Svendgaard Laboratories Limited disclosed shareholder-approved modifications, dated 29th Jul'26, regarding the utilization of ₹29.99 crore raised via a preferential issue on 4th Jun'24. For the quarter ended 30th Sep'26, capital expenditure and business expansion allocation was increased from ₹5.9999 crore to ₹11.7499 crore (₹8.4946 crore utilized), while group entity infusion was revised down to ₹10.75 crore for strategic and growth initiatives (₹9.625 crore utilized). General corporate purpose allocation remained unchanged at ₹7.50 crore and is fully utilized. Zero deviation was reported against the modified objects.

Original exchange filing (PDF)

More announcements from JHS Svendgaard Laboratories Ltd

All JHS Svendgaard Laboratories Ltd announcements